PAID ADVERTISEMENT
This program will discuss the challenges and unmet needs in LDL-C management despite the availability of statins. Discover how appropriate patients with ASCVD and persistently elevated LDL-C levels may benefit from LEQVIO on top of a maximally tolerated statin and healthy diet.
Don’t miss the in-depth dive into the clinical efficacy and safety data, mechanism of action, dosing schedule, and administration.
Sunday, November 6, 2022
11:00 AM–11:45 AM CST
Learning Studio 1
Jason Lecocq, MD, MBA
Senior Medical Director, Atherosclerosis, US CLINICAL DEVELOPMENT & MEDICAL AFFAIRS, Cardiovascular & Metabolism, Novartis Pharmaceuticals Corporation
INDICATION
LEQVIO (inclisiran) injection is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional lowering of low-density lipoprotein cholesterol (LDL-C). Limitations of Use: The effect of LEQVIO on cardiovascular morbidity and mortality has not been determined.
IMPORTANT SAFETY INFORMATION
Adverse reactions in clinical trials (≥3% of patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, urinary tract infection, diarrhea, bronchitis, pain in extremity and dyspnea.
Click here for LEQVIO full Prescribing Information.
This event is not part of the official Scientific Sessions 2022 as planned by the AHA Committee on Scientific Sessions Program.
The American Heart Association (AHA) does not endorse any commercial products or programs. The links provided within this site are for convenience only, and are not an endorsement of either the linked-to entity, product or service. AHA makes no warranties of any kind, express or implied, with regard to its third-party vendor websites.
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080 © 2022 Novartis 10/22 245776
